Anteris Reports Positive Biomimetic Heart Valve Study Results Anteris Technologies (Nasdaq:AVR) announced one-year clinical outcomes for its DurAVR transcatheter heart valve (THV) in sympt…
Landmark Report Exposes Conflict of Interest in Canadian Lobbying A recent study by FMinus reveals that Canadian lobbyists represent both …
European Parliament Considers Banning Russian Media The European Parliament is weighing whether to ban access to Russian websites, such as…
Market Watch: Regeneron, UPS, and Zebra Regeneron (REGN) has seemingly overcome its bear phase, with shares rebounding from $550-$575 to o…
Eddie Glaude Jr. on Challenging MAGA Eddie Glaude Jr. suggests a simple response to false claims made by Trump supporters: "You're lying."…
Preventing Infections after Surgery for Lower Limb Arteries Peripheral artery disease (PAD) is a condition where the arteries that supply …
PSG Look to Extend Lead in Ligue 1 Paris St Germain had a successful weekend, winning 3-0 away at Brest and taking the top spot in the tab…
Regeneron's Eylea HD Rejected by FDA Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in Ja…